System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 40539881 DOI: 10.1002/ijc.70011

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma-based collection of 77 patients with locally advanced unresectable esophageal cancer.

Int J Cancer

Authors: Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin-Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva

Affiliations

  • Department of Radiation Oncology, Oncopole Claudius Regaud at Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Centre de Recherches en Cancérologie de Toulouse, CRCT, Toulouse University, Inserm, CNRS, Toulouse, France.
  • Service d'hépato-gastro-entérologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
  • Institut de Cancérologie de l'Ouest: Angers et Saint Herblain, Angers, France.
  • Centre Oscar Lambret, Lille, France.
  • Centre Eugène Marquis, Renne, France.
  • Groupe Hospitalier Bretagne Sud, Lorient, France.
  • Hôpital Privé Arnault Tzanck-Centre Azuréen de Cancérologie, Mougins, France.
  • Institut de Cancérologie de Bourgogne, Dijon, France.
  • CHU de Bordeaux, Bordeaux, France.
  • Centre Val d'Aurelle, Montpellier, France.
  • Centre Armoricain d'Oncologie CARIO, Plérin, France.
  • Nouvelle Clinique des Dentellières, Valenciennes, France.
  • Department of Radiation Oncology, Saint Louis Hospital, AP-HP, Paris, France.
  • UNICANCER, Paris, France.
  • Department of Medical Oncology, Oncopole Claudius Regaud at Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
  • Toulouse 3 Université Paul Sabatier University, Toulouse, France.
  • Department of GI Oncology, Centre Hospitalo Universitaire Rangueil, Toulouse, France.

Abstract

Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high-risk patients in various solid tumors, the lack of specific mutation in esophageal tumor, limits the detection of circulating tumor DNA (ctDNA) with high sensitivity using sequencing-based methods. In this study, we employed a highly sensitive technology of fragmentome assay, previously validated to measure concentration and size distribution of cell-free DNA (cfDNA), to analyze plasma samples from 77 patients with esophageal carcinoma, compared to 15 healthy controls. Total cfDNA concentration was significantly higher in patients than in healthy donors (15.03 ± 1.37 vs. 5.87 ± 0.85 pg/μL, p < .0001). The difference remained significant regardless of tumor histology, location, stage, or nodal involvement and was independent from age or gender. Additionally, we observed a significant reduction in patients fragment length compared to healthy donors. The area under curve from receiver operating characteristic (ROC) of total cfDNA concentration in patients versus healthy donors was 0.86 (p-value <.0001). The threshold of 7.5 pg/μL yielded a sensitivity of 81% and a specificity of 80%. This prospective study demonstrated that blood samples from patients exhibit a greater global concentration of smaller fragments compared to healthy controls. These findings support further longitudinal evaluation to determine the predictive and prognostic value of cfDNA in locally advanced unresectable esophageal carcinoma.

MeSH

Neoplasms, Esophageal Neoplasms, Liquid Biopsy, Plasma